Opposition to Food and Drug Administration acting commissioner Janet Woodcock has increased after the agency approved Biogen’s controversial Alzheimer’s drug. Critics have argued that Woodcock is too friendly with the drug industry. (Politico)
Sanofi announced that sutimlimab hit all three primary endpoints in its Phase III CADENZA trial. The drug, which treats cold agglutinin disease, experienced a setback last year when the FDA rejected its application for approval. (Endpoints News)
Half of Manhattan’s one million office workers may be returning to the office by September. Public health experts say there are steps offices can take to reopen safely – like flushing out water, upgrading ventilation and adjusting staff schedules. (The New York Times)
Dozens of states are reducing pandemic reporting as cases drop, raising alarm among public health experts. Several states stopped reporting daily cases, hospitalizations and deaths, which could complicate the identification of fresh outbreaks. (NPR)
Amyotrophic lateral sclerosis (ALS) advocates are frustrated that the FDA has approved Biogen’s controversial Alzheimer’s drug ahead of any ALS drugs. The FDA granted Aduhelm accelerated approval, but argued that there isn’t enough evidence to do the same for ALS drugs. (STAT)
